Under normal physiological conditions, platelet production maintains a platelet count at an appropriate level. Treatment of mice with anti-platelet antibodies results in a rapid specific immunodepletion of platelets. After the anti-platelet antibodies are cleared, recovery of the platelet count ensues. NFYPs are produced, and, during the recovery phase, a transient loss of GPVI-specific function can be detected. Time-dependent exposure to vascular and blood-specific components as the NFYPs circulate may subsequently enable GPVI function as a normal platelet count is restored.